More recently, the pivotal AZA-AML-001 phase 3 trial described no significant association between TP53 mutations and outcome of AML patients treated with azacitidine while TP53 mutations remained associated with shorter OS in the conventional care comparator arm [22]. The gene discussed is TP53; the disease is acute myeloid leukemia.